Lupin's Ceftriaxone gets FDA approval

By Elaine Rigoli

Tampa, Fla., Sept. 14 - Lupin Ltd. said the Food and Drug Administration approved the company's Abbreviated New Drug Application for its Ceftriaxone Injection 10 gram vials (pharmacy bulk pack).

Ceftriaxone is the generic equivalent of Roche's Rocephin (ceftriazone sodium), an antibiotic.

The company had launched the 250 mg, 500 mg, 1g and 2g strengths of Ceftriaxone vials upon Roche's patent expiry in July 2005.

Lupin is a biopharmaceutical company based in Pune City, India.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.